News | Heart Valve Technology | September 20, 2023

Minneapolis Heart Institute Foundation Launches the PROGRESS Clinical Trial to Examine the Safety and Effectiveness of Transcatheter Valve Replacement in Patients with Moderate, Calcific Aortic Stenosis

PROGRESS trial will examine transcatheter aortic valve replacement procedure versus careful observation in patients with moderate, calcific aortic stenosis

IDE supported by data from the MODERATO II randomized pilot study that showed AVIM therapy drove significant and sustained reductions in blood pressure in hypertensive pacemaker patients

September 20, 2023 — The Minneapolis Heart Institute Foundation (MHIF), an internationally renowned cardiovascular research organization, announced the launch of a clinical trial to evaluate transcatheter aortic valve replacement using the Edwards SAPIEN valve platform in patients with moderate, calcific aortic stenosis. MHIF is working with physician research partners to enroll in this study at United Hospital in St. Paul. 

Calcific aortic stenosis (AS) occurs when calcium builds up inside the aortic valve and causes the opening of the valve to become smaller, preventing it from opening and shutting properly. Patients with moderate, calcific AS may or may not experience fatigue, shortness of breath, chest pain, and rapid heartbeat. 

The current treatment for patients with moderate AS is careful observation, or clinical surveillance. Clinical surveillance involves prescribing a regimen of medications accompanied by physician visits every 1-2 years. Valve replacement is currently not recommended until aortic stenosis progresses to a severe state. However, some patients with moderate aortic stenosis and added risk factors may or may not benefit from having their aortic valve replaced. 

The PROGRESS study, led by Bilal Murad, MD, cardiologist and researcher with MHIF at United Hospital in St. Paul and principal investigator for the study, is examining the transcatheter aortic valve replacement (TAVR) procedure versus careful clinical surveillance in patients with moderate, calcific aortic stenosis. TAVR is a minimally invasive procedure that uses a catheter to implant a new valve within the diseased valve. The TAVR procedure is most commonly performed through a small incision in the groin. 

“We are pleased to participate in the PROGRESS trial to contribute to understanding the potential for TAVR as an option for moderate AS,” said Dr. Murad. “There is growing evidence that moderate aortic stenosis may not be as benign as once thought to be and patients struggle with symptoms and impaired quality of life. The goal of this study is to discover if earlier interventions can lead to health improvements in patients by stopping or preventing the worsening of damage to the heart.”  

“The United Heart Team functions as a multidisciplinary team across cardiology, cardiac surgery, imaging, and with robust nursing and advanced provider support to help provide patients with unique treatment options not available everywhere,” said Nishtha Sodhi, MD, cardiologist and researcher with MHIF, and director of the Allina Health Minneapolis Heart Institute Structural Heart and Valve Program at United Hospital. “We are grateful to have been a site chosen to participate in this important study.” 

Patients who qualify for the PROGRESS trial will be randomized between TAVR with the Edwards SAPIEN valve platform and clinical surveillance. This means that patients have a 50/50 chance of being in the TAVR group or the clinical surveillance group. If you are assigned to the clinical surveillance group and your aortic stenosis worsens, your doctor will determine the best treatment option for you – which can include valve replacement. 

The purpose of the trial is to compare results of patients who have their valves replaced at a moderate level of disease versus patients that have their disease monitored. 

Patients interested in participating in the study should contact their doctor to learn more or call 651-241-2730. The United Heart Team is comprised of Bilal Murad, MD; James Kolbeck, MD; Brian Mahoney, MD; Nishtha Sodhi, MD; Gabriel Rodriguez Olivares, MD; Robert Steffen, MD; Carrie Hiemstra, RN; Jessica Timmerman, RN; Danielle Mitchell; Mary Biagini, MSN, RN; and Kelly Jo Powerstorm, MHA-MBA. 

For additional details on the study, visit thePROGRESStrial.com or go to clinicaltrials.gov 

CAUTION: INVESTIGATIONAL DEVICES. The Edwards SAPIEN 3 and Edwards SAPIEN 3 Ultra transcatheter heart valves are investigational devices when used in patients with moderate aortic stenosis. Limited by Federal (USA) law to investigational use only. These devices are not available for marketing or commercial sale in the United States for patients with moderate aortic stenosis. 

For more information: www.mplsheart.org 

 

Related content: 

Edwards Launches Sapien 3 Ultra Resilia Valve Following FDA Approval 

Atlantic Health System’s Morristown Medical Center Randomizes First Patient in World to New Study to Evaluate Treatment with TAVR for Moderate Aortic Stenosis 

Edwards Sapien 3 TAVR Valve Receives Expanded Approval in Canada


Related Content

News | Structural Heart

April 9, 2024 — UC Davis Health cardiology team members are among the first in the country to treat patients with ...

Home April 09, 2024
Home
News | Structural Heart

March 25, 2024 — In a groundbreaking medical advancement, three esteemed cardiologists from CLS Health, Dr. Bahaeddin ...

Home March 25, 2024
Home
News | Structural Heart

March 12, 2024 — Medtronic plc, a global leader in healthcare technology, today announced two late-breaking data ...

Home March 12, 2024
Home
News | Structural Heart

February 20, 2024 — As New Jersey’s leading provider of high-quality cardiac procedures and diagnostic testing and an ...

Home February 20, 2024
Home
News | Structural Heart

February 15, 2024 — Abbott announced that the Circulatory System Devices Panel of the Medical Devices Advisory Committee ...

Home February 15, 2024
Home
News | Structural Heart

February 9, 2024 — Physicians in the Smidt Heart Institute at Cedars-Sinai have achieved two significant firsts ...

Home February 09, 2024
Home
News | Structural Heart

January 4, 2024 — Laguna Tech USA, a privately-held medical technology company dedicated to innovations in structural ...

Home January 04, 2024
Home
News | Structural Heart

December 12, 2023 — Think of them as the Energizer Bunnies of the heart, tiny natural batteries that keep this vital ...

Home December 12, 2023
Home
News | Structural Heart

October 31, 2023 — Edwards Lifesciences Corporation announced one-year results from CLASP IID, the first randomized ...

Home October 31, 2023
Home
News | Structural Heart

October 26, 2023 — Abbott announced data from late-breaking presentations showing the impact of its minimally invasive ...

Home October 26, 2023
Home
Subscribe Now